Relationship Between Biological Profiles and Clinical Evolutions Within the Same Cluster COVID-19 (COVIDCOLLECT)

Study Overview
=================
Brief Summary
-----------------
The hypothesis is that from a cluster defined by a confirmed positive case of COVID-19 and its contact cases, it is possible to study the different expressions and clinical evolutions of COVID-19 infection and to explore the biological profiles related to the observed clinical history. Certain biological determinants (virological, immunological, microbological or gentic) could indeed be correlated with the clinical presentation and/or be useful for personalized care. The main objective is to study the relationship between the biological profiles observed and the clinical evolutions within the same cluster of transmission of the coronavirus SARS-CoV-2 (positive COVID-19 cases and contact subjects).

Detailed Description
-----------------
Subjects with a COVID-19 infection and thei contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel. For the main objective: during the D0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine. For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology.

Official Title
-----------------
Biological Collection for the Study of the Relationship Between the Biological Profiles Observed and the Clinical Evolutions Within the Same Cluster of Transmission of the Coronavirus SARS-CoV-2

Conditions
-----------------
Covid19, Contact Case

Intervention / Treatment
-----------------
* Biological: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Child or adult, no age limit Able to give informed consent to participate in research If a minor participant: consent of the legal representatives If confirmed case COVID-19 (symptomatic or asymptomatic): laboratory result confirming infection with SARS-CoV-2 by RT-PCR or by serology If contact case: people identified as a risk contact according to the criteria of the Amélie.fr health insurance Exclusion Criteria: Subjects under tutorship, curatorship, deprived of liberty, safeguard of justice Refusal of the child Refusal of participation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cohort<br>Biological collection with nasopharyngeal samples, saliva, blood, stool and urine | Biological: Biological collection with nasopharyngeal samples, saliva, blood, stool and urine<br>* Subjects with a COVID-19 infection and their contact cases (identification according to health insurance criteria, see Améli.fr) will be offered a clinical evaluation and the takin of biological samples, whether they are hospitalized or via the outpatient screening channel. For the main objective: during the Day0 visit, the subjects who agreed to participate in the study will have a clinical evaluation according to a standardized questionnaire and a nasopharyngeal swab, saliva, blood, stool and urine. For secondary objectives : longitudinal follow-up will be carried out for 21 days, for index cases and contact cases, whether they have a positive or negative RT-PCR test on D0. A final consultation will be carried out at M3. Nasopharyngeal samples, saliva, blood, stool and urine will be taken on D10 and D21. A blood test will be taken at M3 to carry out a COVID-19 serology.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Virological profile | Nasopharyngeal SARS-CoV-2 viral load at day 0 by RT-PCR (in log or ΔCT) | Day 0 | 
| Virological profile | Nasopharyngeal SARS-CoV-2 viral load at day 0 by RT-PCR (in log or ΔCT) | Day 10 | 
| Virological profile | Nasopharyngeal SARS-CoV-2 viral load at day 0 by RT-PCR (in log or ΔCT) | Day 21 | 
| Virological profile (serology) | SARS-CoV-2 serology by enzyme-linked immunosorbent assays or magnetic chemiluminescence enzyme immunoassay (IgG and IgM titers) | Day 0 | 
| Virological profile (serology) | SARS-CoV-2 serology by enzyme-linked immunosorbent assays or magnetic chemiluminescence enzyme immunoassay (IgG and IgM titers) | Day 10 | 
| Virological profile (serology) | SARS-CoV-2 serology by enzyme-linked immunosorbent assays or magnetic chemiluminescence enzyme immunoassay (IgG and IgM titers) | Day 21 | 
| Immunological profile with blood level for markers of inflammation (cytokine) | cytokine panel by flow cytometry or enzyme-linked immunosorbent assay in pg/mL | Day 0 | 
| Immunological profile with blood level for markers of inflammation (cytokine) | cytokine panel by flow cytometry or enzyme-linked immunosorbent assay in pg/mL | Day 10 | 
| Immunological profile with blood level for markers of inflammation (cytokine) | cytokine panel by flow cytometry or enzyme-linked immunosorbent assay in pg/mL | Day 21 | 
| Immunological profile with blood level for markers of inflammation | markers on immune cell subpopulation by RT-PCR or flow cytometry in CT value or % | Day 0 | 
| Immunological profile with blood level for markers of inflammation | markers on immune cell subpopulation by RT-PCR or flow cytometry in CT value or % | Day 10 | 
| Immunological profile with blood level for markers of inflammation | markers on immune cell subpopulation by RT-PCR or flow cytometry in CT value or % | Day 21 | 
| Biochemical profile by blood dosage of CRP | CRP in mg/l | Day 0 | 
| Biochemical profile by blood dosage of CRP | CRP in mg/l | Day 10 | 
| Biochemical profile by blood dosage of CRP | CRP in mg/l | Day 21 | 
| Biochemical profile by blood dosage of CRP | CRP in mg/l | Day 90 | 
| Biochemical profile by blood dosage of ASAT/ALAT | ASAT/ALAT in U/L | Day 0 | 
| Biochemical profile by blood dosage of ASAT/ALAT | ASAT/ALAT in U/L | Day 10 | 
| Biochemical profile by blood dosage of ASAT/ALAT | ASAT/ALAT in U/L | Day 21 | 
| Biochemical profile by blood dosage of ASAT/ALAT | ASAT/ALAT in U/L | Day 90 | 
| Biochemical profile by blood dosage of LDH | LDH in U/L | Day 0 | 
| Biochemical profile by blood dosage of LDH | LDH in U/L | Day 10 | 
| Biochemical profile by blood dosage of LDH | LDH in U/L | Day 21 | 
| Biochemical profile by blood dosage of LDH | LDH in U/L | Day 90 | 
| Biochemical profile by blood dosage of Lactate | Lactate in mg/l | Day 0 | 
| Biochemical profile by blood dosage of Lactate | Lactate in mg/l | Day 10 | 
| Biochemical profile by blood dosage of Lactate | Lactate in mg/l | Day 21 | 
| Biochemical profile by blood dosage of Lactate | Lactate in mg/l | Day 90 | 
| Biochemical profile by blood dosage of D-Dimer | D-Dimer in µg/L | Day 0 | 
| Biochemical profile by blood dosage of D-Dimer | D-Dimer in µg/L | Day 10 | 
| Biochemical profile by blood dosage of D-Dimer | D-Dimer in µg/L | Day 21 | 
| Biochemical profile by blood dosage of D-Dimer | D-Dimer in µg/L | Day 90 | 
| Biochemical profile by blood dosage of Troponin | Troponin in µg/L | Day 0 | 
| Biochemical profile by blood dosage of Troponin | Troponin in µg/L | Day 10 | 
| Biochemical profile by blood dosage of Troponin | Troponin in µg/L | Day 21 | 
| Biochemical profile by blood dosage of Troponin | Troponin in µg/L | Day 90 | 
| Biochemical profile by blood dosage of Ferritin | Ferritin in µg/L | Day 0 | 
| Biochemical profile by blood dosage of Ferritin | Ferritin in µg/L | Day 10 | 
| Biochemical profile by blood dosage of Ferritin | Ferritin in µg/L | Day 21 | 
| Biochemical profile by blood dosage of RAGE | RAGE (receptor of advanced end glycation products) by enzyme-linked immunosorbent assays in pg/mg total protein | Day 0 | 
| Biochemical profile by blood dosage of RAGE | RAGE (receptor of advanced end glycation products) by enzyme-linked immunosorbent assays in pg/mg total protein | Day 10 | 
| Biochemical profile by blood dosage of RAGE | RAGE (receptor of advanced end glycation products) by enzyme-linked immunosorbent assays in pg/mg total protein | Day 21 | 
| Biochemical profile by blood dosage of SUPAR | SUPAR (soluble urokinase plasminogen activator receptor) by enzyme-linked immunosorbent assays in pg/mg total protein | Day 0 | 
| Biochemical profile by blood dosage of SUPAR | SUPAR (soluble urokinase plasminogen activator receptor) by enzyme-linked immunosorbent assays in pg/mg total protein | Day 10 | 
| Biochemical profile by blood dosage of SUPAR | SUPAR (soluble urokinase plasminogen activator receptor) by enzyme-linked immunosorbent assays in pg/mg total protein | Day 21 | 
| Haematological profile by blood dosage of leukocytes | leukocytes in Giga/L | Day 0 | 
| Haematological profile by blood dosage of leukocytes | leukocytes in Giga/L | Day 10 | 
| Haematological profile by blood dosage of leukocytes | leukocytes in Giga/L | Day 21 | 
| Haematological profile by blood dosage of leukocytes | leukocytes in Giga/L | Day 90 | 
| Haematological profile by blood dosage of Red blood cells | Red blood cells in Tera/L | Day 0 | 
| Haematological profile by blood dosage of Red blood cells | Red blood cells in Tera/L | Day 10 | 
| Haematological profile by blood dosage of Red blood cells | Red blood cells in Tera/L | Day 21 | 
| Haematological profile by blood dosage of Red blood cells | Red blood cells in Tera/L | Day 90 | 
| Haematological profile by blood dosage of Hemoglobin | Hemoglobin in g/dL | Day 0 | 
| Haematological profile by blood dosage of Hemoglobin | Hemoglobin in g/dL | Day 10 | 
| Haematological profile by blood dosage of Hemoglobin | Hemoglobin in g/dL | Day 21 | 
| Haematological profile by blood dosage of Hemoglobin | Hemoglobin in g/dL | Day 90 | 
| Haematological profile by blood dosage of Hematocrit | Hematocrit in % | Day 0 | 
| Haematological profile by blood dosage of Hematocrit | Hematocrit in % | Day 10 | 
| Haematological profile by blood dosage of Hematocrit | Hematocrit in % | Day 21 | 
| Haematological profile by blood dosage of Hematocrit | Hematocrit in % | Day 90 | 
| Haematological profile by blood dosage of Mean corpuscular volume | Mean corpuscular volume in fL | Day 0 | 
| Haematological profile by blood dosage of Mean corpuscular volume | Mean corpuscular volume in fL | Day 10 | 
| Haematological profile by blood dosage of Mean corpuscular volume | Mean corpuscular volume in fL | Day 21 | 
| Haematological profile by blood dosage of Mean corpuscular volume | Mean corpuscular volume in fL | Day 90 | 
| Haematological profile by blood dosage of Mean corpuscular hemoglobin | Mean corpuscular hemoglobin in pg | Day 0 | 
| Haematological profile by blood dosage of Mean corpuscular hemoglobin | Mean corpuscular hemoglobin in pg | Day 10 | 
| Haematological profile by blood dosage of Mean corpuscular hemoglobin | Mean corpuscular hemoglobin in pg | Day 21 | 
| Haematological profile by blood dosage of Mean corpuscular hemoglobin | Mean corpuscular hemoglobin in pg | Day 90 | 
| Haematological profile by blood dosage of average corpuscular concentration of haemoglobin | Average corpuscular concentration of haemoglobin in g/dL | Day 0 | 
| Haematological profile by blood dosage of average corpuscular concentration of haemoglobin | Average corpuscular concentration of haemoglobin in g/dL | Day 10 | 
| Haematological profile by blood dosage of average corpuscular concentration of haemoglobin | Average corpuscular concentration of haemoglobin in g/dL | Day 21 | 
| Haematological profile by blood dosage of average corpuscular concentration of haemoglobin | Average corpuscular concentration of haemoglobin in g/dL | Day 90 | 
| Haematological profile by blood dosage of polynuclear neutrophil | polynuclear neutrophil in Giga/L | Day 0 | 
| Haematological profile by blood dosage of polynuclear neutrophil | polynuclear neutrophil in Giga/L | Day 10 | 
| Haematological profile by blood dosage of polynuclear neutrophil | polynuclear neutrophil in Giga/L | Day 21 | 
| Haematological profile by blood dosage of polynuclear neutrophil | polynuclear neutrophil in Giga/L | Day 90 | 
| Haematological profile by blood dosage of polynuclear eosinophils | polynuclear eosinophils in Giga/L | Day 0 | 
| Haematological profile by blood dosage of polynuclear eosinophils | polynuclear eosinophils in Giga/L | Day 10 | 
| Haematological profile by blood dosage of polynuclear eosinophils | polynuclear eosinophils in Giga/L | Day 21 | 
| Haematological profile by blood dosage of polynuclear eosinophils | polynuclear eosinophils in Giga/L | Day 90 | 
| Haematological profile by blood dosage of polynuclear basophils | polynuclear basophils in Giga/L | Day 0 | 
| Haematological profile by blood dosage of polynuclear basophils | polynuclear basophils in Giga/L | Day 10 | 
| Haematological profile by blood dosage of polynuclear basophils | polynuclear basophils in Giga/L | Day 21 | 
| Haematological profile by blood dosage of polynuclear basophils | polynuclear basophils in Giga/L | Day 90 | 
| Haematological profile by blood dosage of lymphocytes | lymphocytes in Giga/L | Day 0 | 
| Haematological profile by blood dosage of lymphocytes | lymphocytes in Giga/L | Day 10 | 
| Haematological profile by blood dosage of lymphocytes | lymphocytes in Giga/L | Day 21 | 
| Haematological profile by blood dosage of lymphocytes | lymphocytes in Giga/L | Day 90 | 
| Haematological profile by blood dosage of monocytes | monocytes in Giga/L | Day 90 | 
| Haematological profile by blood dosage of monocytes | monocytes in Giga/L | Day 0 | 
| Haematological profile by blood dosage of monocytes | monocytes in Giga/L | Day 10 | 
| Haematological profile by blood dosage of monocytes | monocytes in Giga/L | Day 21 | 
| Haematological profile by blood dosage of platelets | platelets in Giga/L | Day 0 | 
| Haematological profile by blood dosage of platelets | platelets in Giga/L | Day 10 | 
| Haematological profile by blood dosage of platelets | platelets in Giga/L | Day 21 | 
| Haematological profile by blood dosage of platelets | platelets in Giga/L | Day 90 | 
| Haematological profile by blood dosage of activated partial thromboplastin time | activated partial thromboplastin time in second/witness | Day 0 | 
| Haematological profile by blood dosage of activated partial thromboplastin time | activated partial thromboplastin time in second/witness | Day 10 | 
| Haematological profile by blood dosage of activated partial thromboplastin time | activated partial thromboplastin time in second/witness | Day 21 | 
| Haematological profile by blood dosage of activated partial thromboplastin time | activated partial thromboplastin time in second/witness | Day 90 | 
| Haematological profile by blood dosage of fibrinogen | fibrinogen in g/L | Day 0 | 
| Haematological profile by blood dosage of fibrinogen | fibrinogen in g/L | Day 10 | 
| Haematological profile by blood dosage of fibrinogen | fibrinogen in g/L | Day 21 | 
| Haematological profile by blood dosage of fibrinogen | fibrinogen in g/L | Day 90 | 
| Haematological profile by blood dosage of factor V | factor V in % | Day 0 | 
| Haematological profile by blood dosage of factor V | factor V in % | Day 10 | 
| Haematological profile by blood dosage of factor V | factor V in % | Day 21 | 
| Haematological profile by blood dosage of factor V | factor V in % | Day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SARS-CoV-2 salivary viral load | RT-PCR SARS-CoV-2 on saliva in ΔCT value or log10 copies per mL | Day 0 | 
| SARS-CoV-2 salivary viral load | RT-PCR SARS-CoV-2 on saliva in ΔCT value or log10 copies per mL | Day 10 | 
| SARS-CoV-2 salivary viral load | RT-PCR SARS-CoV-2 on saliva in ΔCT value or log10 copies per mL | Day 21 | 
| Comparison of viral sequences | bioinformatic and statistical analyzes of viral sequences (arbitrary unit and p-values) | Day 0 | 
| Comparison of viral sequences | bioinformatic and statistical analyzes of viral sequences (arbitrary unit and p-values) | Day 10 | 
| Comparison of viral sequences | bioinformatic and statistical analyzes of viral sequences (arbitrary unit and p-values) | Day 21 | 
| microbiota analysis | bioinformatic and statistical analyzes of microbiota (arbitrary unit and p-values) | Day 0 | 
| microbiota analysis | bioinformatic and statistical analyzes of microbiota (arbitrary unit and p-values) | Day 10 | 
| microbiota analysis | bioinformatic and statistical analyzes of microbiota (arbitrary unit and p-values) | Day 21 | 
| environmental and societal factors (EPICE) | EPICE score (Assessment of precariousness and health inequalities in examination centers Health) at day 0 from 0 to 100 | Day 0 | 
| environmental and societal factors | eating habits | Day 0 | 
| environmental and societal factors | eating habits | day 10 | 
| environmental and societal factors | eating habits | day 21 | 
| environmental and societal factors | eating habits | day 90 | 
| environmental and societal factors (SF-36) | SF-36 score (quality of life by Gardenal O) from 0 to 100 | Day 0 | 
| environmental and societal factors (SF-36) | SF-36 score (quality of life by Gardenal O) from 0 to 100 | day 10 | 
| environmental and societal factors (SF-36) | SF-36 score (quality of life by Gardenal O) from 0 to 100 | day 21 | 
| environmental and societal factors (SF-36) | SF-36 score (quality of life by Gardenal O) from 0 to 100 | day 90 | 
| environmental and societal factors (Physical activity) | Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100 | Day 0 | 
| environmental and societal factors (Physical activity) | Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100 | day 10 | 
| environmental and societal factors (Physical activity) | Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100 | day 21 | 
| environmental and societal factors (Physical activity) | Physical activity score (by J. Ricci et L. Gagnon test for adults and ActiFitY test for children) from 0 to 100 | day 90 | 
| body weight | body weight in kg | Day 0 | 
| body weight | body weight in kg | day 10 | 
| body weight | body weight in kg | day 21 | 
| body weight | body weight in kg | day 90 | 
| oxygen saturation | oxygen saturation in % | Day 0 | 
| oxygen saturation | oxygen saturation in % | day 10 | 
| oxygen saturation | oxygen saturation in % | day 21 | 
| oxygen saturation | oxygen saturation in % | day 90 | 
| Respiratory rate | Respiratory rate per minute | Day 0 | 
| Respiratory rate | Respiratory rate per minute | day 10 | 
| Respiratory rate | Respiratory rate per minute | day 21 | 
| Respiratory rate | Respiratory rate per minute | day 90 | 
| cardiac frequency | cardiac frequency per minute | Day 0 | 
| cardiac frequency | cardiac frequency per minute | day 10 | 
| cardiac frequency | cardiac frequency per minute | day 21 | 
| cardiac frequency | cardiac frequency per minute | day 90 | 
| lung damage | Lung damage on auscultation in terms of presence/absence | Day 0 | 
| lung damage | Lung damage on auscultation in terms of presence/absence | day 10 | 
| lung damage | Lung damage on auscultation in terms of presence/absence | day 21 | 
| lung damage | Lung damage on auscultation in terms of presence/absence | day 90 | 
| lung evolution | CT san in terms of normal/abnormal (children and pregnant women not concerned) | day 90 | 
| blood pressure | Dysatolic/systolic blood pressure in mmHg | Day 0 | 
| blood pressure | Dysatolic/systolic blood pressure in mmHg | day 10 | 
| blood pressure | Dysatolic/systolic blood pressure in mmHg | day 21 | 
| blood pressure | Dysatolic/systolic blood pressure in mmHg | day 90 | 
| body temperature | Body temperature in °C | Day 0 | 
| body temperature | Body temperature in °C | day 10 | 
| body temperature | Body temperature in °C | day 21 | 
| body temperature | Body temperature in °C | day 90 | 
| clinical exam (skin) | Skin mottling in terms of presence/absence | Day 0 | 
| clinical exam (skin) | Skin mottling in terms of presence/absence | day 10 | 
| clinical exam (skin) | Skin mottling in terms of presence/absence | day 21 | 
| clinical exam (skin) | Skin mottling in terms of presence/absence | day 90 | 
| clinical exam (polypnea) | polypnea in terms of presence/absence | Day 0 | 
| clinical exam (polypnea) | polypnea in terms of presence/absence | day 10 | 
| clinical exam (polypnea) | polypnea in terms of presence/absence | day 21 | 
| clinical exam (polypnea) | polypnea in terms of presence/absence | day 90 | 
| denutrition | denutrition in terms of presence/absence | Day 0 | 
| denutrition | denutrition in terms of presence/absence | day 10 | 
| denutrition | denutrition in terms of presence/absence | day 21 | 
| denutrition | denutrition in terms of presence/absence | day 90 | 
| Antibiotic treatment | Antibiotic treatment in terms of presence/absence with precision if necessary | Day 0 | 
| Antibiotic treatment | Antibiotic treatment in terms of presence/absence with precision if necessary | day 10 | 
| Antibiotic treatment | Antibiotic treatment in terms of presence/absence with precision if necessary | day 21 | 
| Antibiotic treatment | Antibiotic treatment in terms of presence/absence with precision if necessary | day 90 | 
| Steroidal anti-inflammatory treatment | Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary | Day 0 | 
| Steroidal anti-inflammatory treatment | Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary | day 10 | 
| Steroidal anti-inflammatory treatment | Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary | day 21 | 
| Steroidal anti-inflammatory treatment | Steroidal anti-inflammatory treatment in terms of presence/absence with precision if necessary | day 90 | 
| Anti-diabetic treatment | Anti-diabetic treatment in terms of presence/absence with precision if necessary | Day 0 | 
| Anti-diabetic treatment | Anti-diabetic treatment in terms of presence/absence with precision if necessary | day 10 | 
| Anti-diabetic treatment | Anti-diabetic treatment in terms of presence/absence with precision if necessary | day 21 | 
| Anti-diabetic treatment | Anti-diabetic treatment in terms of presence/absence with precision if necessary | day 90 | 
| Gastric protector treatment | Gastric protector treatment in terms of presence/absence with precision if necessary | Day 0 | 
| Gastric protector treatment | Gastric protector treatment in terms of presence/absence with precision if necessary | day 10 | 
| Gastric protector treatment | Gastric protector treatment in terms of presence/absence with precision if necessary | day 21 | 
| Gastric protector treatment | Gastric protector treatment in terms of presence/absence with precision if necessary | day 90 | 
| chills | chills in terms of presence/absence | Day 0 | 
| chills | chills in terms of presence/absence | day 10 | 
| chills | chills in terms of presence/absence | day 21 | 
| chills | chills in terms of presence/absence | day 90 | 
| Myalgia | Myalgia in terms of presence/absence | Day 0 | 
| Myalgia | Myalgia in terms of presence/absence | day 10 | 
| Myalgia | Myalgia in terms of presence/absence | day 21 | 
| Myalgia | Myalgia in terms of presence/absence | day 90 | 
| Anorexia | Anorexia in terms of presence/absence | Day 0 | 
| Anorexia | Anorexia in terms of presence/absence | day 10 | 
| Anorexia | Anorexia in terms of presence/absence | day 21 | 
| Anorexia | Anorexia in terms of presence/absence | day 90 | 
| Rhinitis | Rhinitis in terms of presence/absence | Day 0 | 
| Rhinitis | Rhinitis in terms of presence/absence | day 10 | 
| Rhinitis | Rhinitis in terms of presence/absence | day 21 | 
| Rhinitis | Rhinitis in terms of presence/absence | day 90 | 
| Confusion | Confusion in terms of presence/absence | Day 0 | 
| Confusion | Confusion in terms of presence/absence | day 10 | 
| Confusion | Confusion in terms of presence/absence | day 21 | 
| Confusion | Confusion in terms of presence/absence | day 90 | 
| Asthenia | Asthenia in terms of presence/absence | Day 0 | 
| Asthenia | Asthenia in terms of presence/absence | day 10 | 
| Asthenia | Asthenia in terms of presence/absence | day 21 | 
| Asthenia | Asthenia in terms of presence/absence | day 90 | 
| Falls at home | Falls at home in terms of presence/absence | Day 0 | 
| Falls at home | Falls at home in terms of presence/absence | day 10 | 
| Falls at home | Falls at home in terms of presence/absence | day 21 | 
| Falls at home | Falls at home in terms of presence/absence | day 90 | 
| Insomnia | Insomnia in terms of presence/absence | Day 0 | 
| Insomnia | Insomnia in terms of presence/absence | day 10 | 
| Insomnia | Insomnia in terms of presence/absence | day 21 | 
| Insomnia | Insomnia in terms of presence/absence | day 90 | 
| Angina | Angina in terms of presence/absence | Day 0 | 
| Angina | Angina in terms of presence/absence | day 10 | 
| Angina | Angina in terms of presence/absence | day 21 | 
| Angina | Angina in terms of presence/absence | day 90 | 
| Ageusia | Ageusia in terms of presence/absence | Day 0 | 
| Ageusia | Ageusia in terms of presence/absence | day 10 | 
| Ageusia | Ageusia in terms of presence/absence | day 21 | 
| Ageusia | Ageusia in terms of presence/absence | day 90 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | Day 0 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | day 2 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | day 4 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | day 6 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | day 8 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | day 10 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | day 21 | 
| Respiratory complaints | Respiratory complaints in term of SRIpr score from 0 to 100 | day 90 | 
| transmission rate | Rate of viral transmission determine by bioinformatic and statistical analyzes in % | Day 0 | 
| transmission rate | Rate of viral transmission determine by bioinformatic and statistical analyzes in % | day 10 | 
| transmission rate | Rate of viral transmission determine by bioinformatic and statistical analyzes in % | day 21 | 
| prolonged viral shedding | Prolonged viral shedding evaluate by RT-PCR (CT value or log10 copies per mL) | between day 0 and day 21 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
SARS-CoV-2, COVID19, Confirmed case, Biological collection, contact case, cluster